Loading
A phase 2 trial of HLX43 DOSE 1 (2.0 mg/kg) in non-small-cell lung cancer, run by Shanghai Henlius Biotech, now recruiting.
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT06907615 by Shanghai Henlius Biotech, with 243 participants planned, started 2025-06-09 and due to reach its primary completion in 2028-04-20. Interventions recorded: HLX43 DOSE 1 (2.0 mg/kg) and HLX43 DOSE 2 (2.5 mg/kg).
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech, Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech, Non-small-cell lung cancer and the tag pipeline.